✦ LIBER ✦

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model

✍ Scribed by Ruifang Mi; Jianhui Ma; Dechang Zhang; Limin Li; Hongbing Zhang

Book ID: 118651228
Publisher: Elsevier
Year: 2009
Tongue: Chinese
Weight: 310 KB
Volume: 36
Category: Article
ISSN: 1673-8527
DOI: 10.1016/s1673-8527(08)60124-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activation of Ras/MAPK and mTOR pathways

Activation of Ras/MAPK and mTOR pathways in hepatocellular carcinoma: Tumor growth inhibition with Ras/mTOR pathway abrogation by a novel combination of Sorafenib and rapamycin

✍ Philippa H. Newell; Augusto Villanueva; Judit Peix; Isabel Fiel; Swan Thung; Ste 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Combination of a rapamycin analog (CCI-7

Combination of a rapamycin analog (CCI-779) and interferon-γ is more effective than single agents in treating a mouse model of tuberous sclerosis complex

✍ Laifong Lee; Paul Sudentas; Sandra L. Dabora 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 397 KB

## Abstract Tuberous sclerosis complex (TSC) is a familial tumor syndrome characterized by the development of hamartomas in the brain, heart, kidney, and skin. Disease‐causing mutations in the __TSC1__ or __TSC2__ gene result in constitutive activation of the highly conserved mTOR signal transducti

The use of everolimus to target carcinog

The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report

✍ Kim, Hye; Kim, Seung; Kang, Seok; Sung, Deuk; Kim, Chul; Shin, Sang; Kim, Yeul; 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 454 KB

Increase of cyclooxygenase-2 inhibition

Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer

✍ De-Qing Zhang, Qiang Guo, Jian-Hong Zhu… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 510 KB

Commentary on Targeting AKT/mTOR and ERK

Commentary on Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model: Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C, Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY

✍ Haojie Huang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 69 KB